AUTHORS
Krit Ritthipichai, PhD, Maya A. Jerald, DVM2, Ian Frank, BS3, Ruihua A. Chen, PhD4, Edward A. Garcia, B.S.5, Arjun Jayakrishnan6, Taekyoung Kwak, PhD7, Tiffany Razabdouski, B.S.8, Erika Adriana Eksioglu, PhD9, Michael Turner, PhD10, James A. Bianco, MD11
AFFILIATIONS
1 TuHURA Biosciences, Tampa, Florida, United States
2 TuHURA Biosciences, Tampa, Florida, United States
3 TuHURA Biosciences, Tampa, Florida, United States
4 TuHURA Biosciences, Tampa, Florida, United States
5 TuHURA Biosciences, Tampa, Florida, United States
6 TuHURA Biosciences, Tampa, Florida, United States
7 TuHURA Biosciences, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 TuHURA Biosciences, Tampa, Florida, United States
11 TuHURA Biosciences, Tampa, Florida, United States
ABSTRACT
Regulatory T cells (Tregs) play essential roles in maintaining peripheral tolerance and limiting collateral tissue damage during inflammation under normal physiological conditions. In cancer, however, these same suppressive mechanisms—including expression of co-inhibitory receptors (CTLA-4, LAG-3, and TIGIT), secretion of inhibitory cytokines (IL-10 and TGF-β), and IL-2 sequestration through high CD25 expression—attenuate effector immune cell activation and function, thereby promoting immune evasion and limiting the efficacy of cancer immunotherapy. Pharmacologic modulation of Treg suppressive function may therefore represent a therapeutic strategy for both cancer and autoimmune diseases.
Emerging evidence shows that delta-opioid receptor (DOR) signaling regulates immune cell function. We previously reported elevated DOR expression in immunosuppressive myeloid populations, including myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) (Cheng et al. (2025) Blood, 146(Suppl 1): 622 and Ritthipichai et al. (2025) Blood, 146(Suppl 1): 1201). Pharmacologic inhibition of DOR reduced expression of multiple immunosuppressive genes and attenuated MDSC-mediated suppression of T-cell proliferation. In the present study, we investigated whether modulation of DOR signaling regulates Treg differentiation.
Single-cell suspensions prepared from 4T1 murine mammary tumors were analyzed for DOR expression across tumor-infiltrating immune cell populations by flow cytometry. DOR expression kinetics were evaluated during in vitro-induced regulatory T-cell (iTreg) differentiation using purified murine CD4? T cells stimulated with ImmunoCult™ (anti-CD2/CD3/CD28) and TGF-β for 4 days. The effects of the DOR agonist KNT-127, the DOR antagonist HURA-009, and the mu-opioid receptor (MOR) agonist DAMGO on iTreg differentiation were assessed by flow cytometry. DOR signaling was validated using a homogeneous time-resolved fluorescence (HTRF)-based cAMP assay in DOR-overexpressing CHO cells.
In 4T1 tumors, DOR expression was highest in myeloid cells (CD45?CD11b?; >95%, 96.55–97.77%) and was also detected in tumor-infiltrating Tregs (CD3?CD4?CD25?CD127-; >65%, 65.18–82.03%). Consistent with these findings, DOR expression on iTregs increased from less than 10% at baseline to approximately 50% within 24 hours of stimulation with ImmunoCult™ and TGF-β. By 96 hours, the proportions of DOR-positive iTregs (CD3?CD4?CD25?FOXP3+) and activated effector T cells (CD3?CD4?CD25?FOXP3?) were comparable (~75%); however, DOR expression levels, measured by mean fluorescence intensity (MFI), remained higher in iTregs. Functional receptor activity was confirmed by cAMP assay, in which KNT-127 inhibited forskolin-induced cAMP accumulation with an EC50 of 0.21 nM, consistent with activation of Gi-coupled DOR signaling. Pharmacologic activation of DOR with KNT-127 increased the proportion of iTregs compared with DMSO-treated controls (DMSO: 31.09–31.37%; KNT-127: 49.45–50.27%). This effect was reversed by the DOR antagonist HURA-009 (KNT-127 + HURA-009: 27.15–34.20%). In contrast, activation of the MOR with the enkephalin derivative (H-Tyr-D-Ala-Gly-N-MePhe-Gly-ol) DAMGO, a highly selective MOR agonist, failed to increase the fraction of iTregs (DAMGO: 30.82–37.57%), supporting a specific role for DOR, rather than MOR, signaling in promoting iTreg differentiation.
Our study demonstrates a role of DOR modulation in Treg differentiation. Pharmacologic activation of DOR enhances iTreg differentiation in a DOR-dependent and receptor-specific manner, whereas blocking DOR activation with a DOR antagonist abrogates this effect. Strategies to deplete or inhibit Tregs are being actively pursued to enhance antitumor immunity, whereas approaches that expand or stabilize Tregs are of interest for the treatment of autoimmune diseases and transplantation. Ongoing studies are evaluating how DOR signaling also regulates Treg suppressive functions such as suppression of effector T-cell proliferation, immunosuppressive cytokine secretion, and contact-dependent suppression via co-inhibitory receptors. Together, these findings establish DOR as a regulator of Treg biology and represent a novel pharmacologic approach to either enhance or attenuate Treg-mediated immune regulation in cancer, transplantation, and autoimmune diseases.
DISCLOSURES
Krit Ritthipichai, PhD: TuHURA Biosciences - Current holder of stock options in a privately-held company; TuHURA Biosciences - Research Funding; TuHURA Biosciences - Current Employment